Gilead Sciences (NASDAQ:GILD) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft initiated coverage on shares of Gilead Sciences (NASDAQ:GILD) in a report published on Thursday, Marketbeat Ratings reports. The firm issued a hold rating and a $75.00 price target on the biopharmaceutical company’s stock.

GILD has been the subject of several other research reports. Piper Sandler lowered their price objective on shares of Gilead Sciences from $105.00 to $100.00 and set an overweight rating for the company in a research report on Monday, July 24th. UBS Group lowered their price objective on Gilead Sciences from $85.00 to $84.00 and set a neutral rating for the company in a research note on Wednesday, November 8th. Bank of America upgraded Gilead Sciences from a neutral rating to a buy rating and lifted their target price for the stock from $88.00 to $95.00 in a report on Friday, September 8th. HSBC started coverage on Gilead Sciences in a report on Wednesday, September 6th. They set a reduce rating and a $71.00 price target on the stock. Finally, Royal Bank of Canada lifted their price objective on shares of Gilead Sciences from $83.00 to $84.00 and gave the stock a sector perform rating in a research note on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of Hold and a consensus target price of $88.61.

Gilead Sciences Trading Up 1.3 %

Shares of Gilead Sciences stock opened at $75.92 on Thursday. The company has a quick ratio of 0.91, a current ratio of 1.34 and a debt-to-equity ratio of 1.08. The firm has a market cap of $94.60 billion, a price-to-earnings ratio of 16.29, a PEG ratio of 0.87 and a beta of 0.32. Gilead Sciences has a twelve month low of $72.87 and a twelve month high of $89.74. The business has a 50-day moving average price of $76.85 and a 200-day moving average price of $77.49.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.38. The business had revenue of $7.05 billion for the quarter, compared to the consensus estimate of $6.81 billion. Gilead Sciences had a return on equity of 39.30% and a net margin of 21.45%. The company’s revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.90 EPS. Equities research analysts anticipate that Gilead Sciences will post 6.73 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 3.95%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 64.38%.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the sale, the chief financial officer now directly owns 104,003 shares in the company, valued at $8,320,240. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Gilead Sciences news, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction on Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total transaction of $400,000.00. Following the sale, the chief financial officer now owns 104,003 shares of the company’s stock, valued at approximately $8,320,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 1,501 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total value of $115,561.99. Following the sale, the insider now owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank Julius Baer & Co. Ltd Zurich lifted its holdings in shares of Gilead Sciences by 98,797.6% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 394,005,889 shares of the biopharmaceutical company’s stock valued at $30,366,034,000 after purchasing an additional 393,607,491 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Gilead Sciences by 324.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after buying an additional 13,764,169 shares during the last quarter. Norges Bank acquired a new stake in Gilead Sciences in the fourth quarter worth about $1,115,186,000. Moneta Group Investment Advisors LLC grew its stake in shares of Gilead Sciences by 96,759.8% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 10,111,194 shares of the biopharmaceutical company’s stock worth $868,046,000 after acquiring an additional 10,100,755 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Gilead Sciences by 70.6% in the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock valued at $921,006,000 after purchasing an additional 6,410,047 shares during the last quarter. Hedge funds and other institutional investors own 82.33% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.